EIM
PRQR icon

Essex Investment Management’s ProQR Therapeutics PRQR Stock Holding History

Essex Investment Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30,274
Closed -$586K – 516
2018
Q3 		$586K Sell
30,274
-52,477
-63% -$558K 0.07% 288
2018
Q2 		$604K Buy
+82,751
New +$417K 0.08% 278

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Essex Investment Management's PRQR Position: Q4 2018 in Review

Essex Investment Management sold out of ProQR Therapeutics (PRQR) in Q4 2018, closing a stake of 30,274 shares — an estimated $586K sold.

Essex Investment Management first reported a position in PRQR in Q2 2018 and held it in 2 quarters. The position peaked at $604K in Q2 2018. 57 funds tracked by Wall St. Rank hold PRQR as of Q4 2018.

  • Essex Investment Management reported no remaining ProQR Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 30,274 ProQR Therapeutics shares in Q4 2018, an estimated $586K.
  • Essex Investment Management first reported a position in ProQR Therapeutics in Q2 2018 and held it in 2 quarters.
  • Essex Investment Management's ProQR Therapeutics position peaked at $604K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.